| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Access to cancer medicine in low-resource settings
|
The Lancet Oncology,
|
|
2013
|
14 |
1 |
p. 1-
1 p.
|
article
|
| 2 |
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial
|
Mackey, John R
|
|
2013
|
14 |
1 |
p. 72-80
9 p.
|
article
|
| 3 |
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial
|
Goss, Paul E
|
|
2013
|
14 |
1 |
p. 88-96
9 p.
|
article
|
| 4 |
Approaching the era of personalised therapy for liver cancer?
|
Abou-Alfa, Ghassan K
|
|
2013
|
14 |
1 |
p. 7-8
2 p.
|
article
|
| 5 |
Aristolochia: the malignant truth
|
Krell, Daniel
|
|
2013
|
14 |
1 |
p. 25-26
2 p.
|
article
|
| 6 |
A step towards treating KRAS-mutant NSCLC
|
Goldberg, Sarah B
|
|
2013
|
14 |
1 |
p. 3-5
3 p.
|
article
|
| 7 |
Brain metastases from HER2-positive breast cancer
|
Susheela, Sridhar Papaiah
|
|
2013
|
14 |
1 |
p. e3-
1 p.
|
article
|
| 8 |
Brain metastases from HER2-positive breast cancer
|
Nieder, Carsten
|
|
2013
|
14 |
1 |
p. e2-e3
nvt p.
|
article
|
| 9 |
Brain metastases from HER2-positive breast cancer – Authors' reply
|
Bachelot, Thomas
|
|
2013
|
14 |
1 |
p. e3-e4
nvt p.
|
article
|
| 10 |
Burma: health reforms slow to reach cancer patients
|
Kenyon, Georgina
|
|
2013
|
14 |
1 |
p. 17-18
2 p.
|
article
|
| 11 |
China tackles illness-led poverty as financing gap grows
|
Ouyang, Yadan
|
|
2013
|
14 |
1 |
p. 19-
1 p.
|
article
|
| 12 |
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
|
Bennouna, Jaafar
|
|
2013
|
14 |
1 |
p. 29-37
9 p.
|
article
|
| 13 |
Correction to Lancet Oncol 2012; 13: 549, 554
|
|
|
2013
|
14 |
1 |
p. e5-
1 p.
|
article
|
| 14 |
Cutaneous toxicities of RAF inhibitors
|
Anforth, Rachael
|
|
2013
|
14 |
1 |
p. e11-e18
nvt p.
|
article
|
| 15 |
Docetaxel pricing threatens Australian chemotherapy services
|
Kirby, Tony
|
|
2013
|
14 |
1 |
p. e8-
1 p.
|
article
|
| 16 |
End-of-life discussions and care received
|
Burki, Talha Khan
|
|
2013
|
14 |
1 |
p. 16-
1 p.
|
article
|
| 17 |
Everolimus for tuberous sclerosis complex
|
Bennet, Neil
|
|
2013
|
14 |
1 |
p. e6-
1 p.
|
article
|
| 18 |
Genome sequencing programme announced in the UK
|
Mayor, Susan
|
|
2013
|
14 |
1 |
p. e10-
1 p.
|
article
|
| 19 |
Healthtalkonline
|
Yaqub, Farhat
|
|
2013
|
14 |
1 |
p. 26-27
2 p.
|
article
|
| 20 |
Intraoperative ultrasound guidance for palpable breast cancer excision (COBALT trial): a multicentre, randomised controlled trial
|
Krekel, Nicole MA
|
|
2013
|
14 |
1 |
p. 48-54
7 p.
|
article
|
| 21 |
Investigators ring the smoke alarm at US airports
|
Benmaamar, Ramla
|
|
2013
|
14 |
1 |
p. e7-
1 p.
|
article
|
| 22 |
Lapatinib in early breast cancer—questions to be resolved
|
Lønning, Per Eystein
|
|
2013
|
14 |
1 |
p. 11-12
2 p.
|
article
|
| 23 |
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
|
Bachelot, Thomas
|
|
2013
|
14 |
1 |
p. 64-71
8 p.
|
article
|
| 24 |
Molecular diagnostics in paediatric glial tumours
|
Kim, Joon-Hyung
|
|
2013
|
14 |
1 |
p. e19-e27
nvt p.
|
article
|
| 25 |
Mortality
|
Burki, Talha Khan
|
|
2013
|
14 |
1 |
p. 28-
1 p.
|
article
|
| 26 |
NICE guidance on ipilimumab for previously treated advanced melanoma
|
Diaz, Richard A
|
|
2013
|
14 |
1 |
p. 23-24
2 p.
|
article
|
| 27 |
NICE guidance on vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
|
Perampaladas, Kumar
|
|
2013
|
14 |
1 |
p. 21-22
2 p.
|
article
|
| 28 |
Novel therapeutic target in aggressive paediatric AMKL
|
Gilbert, Judith A
|
|
2013
|
14 |
1 |
p. e6-
1 p.
|
article
|
| 29 |
Ponatinib for resistant Ph chromosome-positive leukaemia
|
Gilbert, Judith A
|
|
2013
|
14 |
1 |
p. e9-
1 p.
|
article
|
| 30 |
Primary systemic treatment of breast-cancer brain metastases
|
Bartsch, Rupert
|
|
2013
|
14 |
1 |
p. 8-9
2 p.
|
article
|
| 31 |
Prognosis of renal-cell carcinoma: recognising host genetics
|
Sonpavde, Guru
|
|
2013
|
14 |
1 |
p. 9-10
2 p.
|
article
|
| 32 |
Promising drug for advanced prostate cancer
|
Benmaamar, Ramla
|
|
2013
|
14 |
1 |
p. e10-
1 p.
|
article
|
| 33 |
Reducing reoperation rates after breast-conserving surgery
|
Jatoi, Ismail
|
|
2013
|
14 |
1 |
p. 5-6
2 p.
|
article
|
| 34 |
Regorafenib for treatment of advanced colorectal cancer
|
Cagney, Hannah
|
|
2013
|
14 |
1 |
p. e7-
1 p.
|
article
|
| 35 |
2012 San Antonio Breast Cancer Symposium
|
Brierley, Rob
|
|
2013
|
14 |
1 |
p. 20-
1 p.
|
article
|
| 36 |
Screening methods for geriatric frailty
|
Mathoulin-Pélissier, Simone
|
|
2013
|
14 |
1 |
p. e1-e2
nvt p.
|
article
|
| 37 |
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
|
Jänne, Pasi A
|
|
2013
|
14 |
1 |
p. 38-47
10 p.
|
article
|
| 38 |
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study
|
Schutz, Fabio AB
|
|
2013
|
14 |
1 |
p. 81-87
7 p.
|
article
|
| 39 |
Slow but meaningful progress in fight against ovarian cancer
|
Burki, Talha Khan
|
|
2013
|
14 |
1 |
p. e8-
1 p.
|
article
|
| 40 |
Stereotactic body radiotherapy for oligometastases
|
Tree, Alison C
|
|
2013
|
14 |
1 |
p. e28-e37
nvt p.
|
article
|
| 41 |
The conundrum of clinical trials in adult germ-cell tumours
|
Powles, Thomas
|
|
2013
|
14 |
1 |
p. 14-15
2 p.
|
article
|
| 42 |
The era of big trials is over
|
Rooney, Melissa
|
|
2013
|
14 |
1 |
p. 12-14
3 p.
|
article
|
| 43 |
The price of autonomy: should we offer individuals a choice of colorectal cancer screening strategies?
|
van Dam, Leonie
|
|
2013
|
14 |
1 |
p. e38-e46
nvt p.
|
article
|
| 44 |
Three-dimensional imaging improves mammogram accuracy
|
Pirisi, Angela
|
|
2013
|
14 |
1 |
p. e9-
1 p.
|
article
|
| 45 |
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|
Santoro, Armando
|
|
2013
|
14 |
1 |
p. 55-63
9 p.
|
article
|
| 46 |
VEGF inhibition beyond tumour progression
|
Grothey, Axel
|
|
2013
|
14 |
1 |
p. 2-3
2 p.
|
article
|
Journal description